Edgar Davidson
Overview
Explore the profile of Edgar Davidson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
2504
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Banik S, Deng X, Davidson E, Storz U, Doranz B
Nat Biotechnol
. 2025 Feb;
43(2):170-174.
PMID: 39953223
No abstract available.
2.
Hastie K, Salie Z, Ke Z, Halfmann P, DeWald L, McArdle S, et al.
Nat Commun
. 2025 Feb;
16(1):1293.
PMID: 39900911
Monoclonal antibodies (mAbs) against Ebola virus (EBOV) glycoprotein (GP) are the standard of care for Ebola virus disease (EVD). Anti-GP mAbs targeting the stalk and membrane proximal external region (MPER)...
3.
Yang M, Yuan T, Chan K, Ding L, Han Z, Franco H, et al.
Antib Ther
. 2024 Jun;
7(2):164-176.
PMID: 38933534
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve, escape coronavirus disease 2019 therapeutics and vaccines, and jeopardize public health. To combat SARS-CoV-2 antigenic escape, we developed a rapid,...
4.
Wolters R, Ferguson J, Nunez I, Chen E, Sornberger T, Myers L, et al.
Immunity
. 2024 Jun;
57(6):1413-1427.e9.
PMID: 38823390
Influenza B viruses (IBVs) comprise a substantial portion of the circulating seasonal human influenza viruses. Here, we describe the isolation of human monoclonal antibodies (mAbs) that recognized the IBV neuraminidase...
5.
Saphire E, Salie Z, Ke Z, Halfmann P, DeWald L, McArdle S, et al.
Res Sq
. 2024 Jan;
PMID: 38196595
Monoclonal antibodies (mAbs) against Ebola virus (EBOV) glycoprotein (GP) are the standard of care for Ebola virus disease (EVD). Anti-GP mAbs targeting the stalk and membrane proximal external region (MPER)...
6.
Sankhala R, Lal K, Jensen J, Dussupt V, Mendez-Rivera L, Bai H, et al.
Nat Commun
. 2024 Jan;
15(1):200.
PMID: 38172512
The repeat emergence of SARS-CoV-2 variants of concern (VoC) with decreased susceptibility to vaccine-elicited antibodies highlights the need to develop next-generation vaccine candidates that confer broad protection. Here we describe...
7.
Lubow J, Levoir L, Ralph D, Belmont L, Contreras M, Cartwright-Acar C, et al.
PLoS Pathog
. 2023 Oct;
19(10):e1011722.
PMID: 37812640
Sequential dengue virus (DENV) infections often generate neutralizing antibodies against all four DENV serotypes and sometimes, Zika virus. Characterizing cross-flavivirus broadly neutralizing antibody (bnAb) responses can inform countermeasures that avoid...
8.
Sankhala R, Dussupt V, Donofrio G, Gromowski G, De La Barrera R, Larocca R, et al.
Cell Rep
. 2023 Aug;
42(8):112942.
PMID: 37561630
Zika virus (ZIKV) is an emerging pathogen that causes devastating congenital defects. The overlapping epidemiology and immunologic cross-reactivity between ZIKV and dengue virus (DENV) pose complex challenges to vaccine design,...
9.
Jensen J, Sankhala R, Dussupt V, Bai H, Hajduczki A, Lal K, et al.
J Virol
. 2023 Jul;
97(7):e0159622.
PMID: 37395646
Novel therapeutic monoclonal antibodies (MAbs) must accommodate comprehensive breadth of activity against diverse sarbecoviruses and high neutralization potency to overcome emerging variants. Here, we report the crystal structure of the...
10.
Dacon C, Peng L, Lin T, Tucker C, Lee C, Cong Y, et al.
Cell Host Microbe
. 2023 Jun;
31(6):1071-1072.
PMID: 37321165
No abstract available.